Autolus Therapeutics plc (NASDAQ:AUTL) is Syncona Portfolio Ltd's Largest Position

Syncona Portfolio Ltd reduced its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 10.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 16,640,720 shares of the company's stock after selling 1,913,904 shares during the quarter. Autolus Therapeutics accounts for about 73.8% of Syncona Portfolio Ltd's investment portfolio, making the stock its largest position. Syncona Portfolio Ltd owned 6.25% of Autolus Therapeutics worth $39,106,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Dumont & Blake Investment Advisors LLC bought a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $35,000. Arkadios Wealth Advisors bought a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $47,000. Capstone Investment Advisors LLC bought a new position in shares of Autolus Therapeutics during the 3rd quarter valued at about $51,000. Avanza Fonder AB bought a new position in shares of Autolus Therapeutics during the 4th quarter valued at about $75,000. Finally, Bellevue Group AG increased its position in shares of Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after purchasing an additional 9,000 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Performance

AUTL stock traded down $0.06 during trading on Friday, hitting $2.01. 443,981 shares of the company traded hands, compared to its average volume of 1,237,897. Autolus Therapeutics plc has a 1 year low of $1.68 and a 1 year high of $6.63. The company has a 50-day moving average of $2.14 and a 200-day moving average of $3.06. The firm has a market capitalization of $534.85 million, a PE ratio of -1.66 and a beta of 2.07.

Remove Ads

Analysts Set New Price Targets

AUTL has been the subject of several analyst reports. Redburn Atlantic upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 target price for the company in a report on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and increased their target price for the company from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $10.40.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.